Oncogenic gene fusions in cancer: from biology to therapy by Stephen V. Liu & Misako Nagasaka & Judith Atz & Flavio Solca & Leonhard Müllauer instant download

Oncogenic gene fusions in cancer: from biology to therapy by Stephen V. Liu & Misako Nagasaka & Judith Atz & Flavio Solca & Leonhard Müllauer instant download

Oncogenic gene fusions occur across a broad range of cancers and are a defining feature of some cancer types. Cancers driven bygene fusion products tend to respond well to targeted therapies, where available; thus, detection of potentially targetableoncogenic fusions is necessary to select optimal treatment. Detection methods include non-sequencing methods, such asfluorescence in situ hybridization and immunohistochemistry, and sequencing methods, such as DNA- and RNA-based nextgeneration sequencing (NGS). While NGS is an efficient way to analyze multiple genes of interest at once, economic and technicalfactors may preclude its use in routine care globally, despite several guideline recommendations. The aim of this review is topresent a summary of oncogenic gene fusions, with a focus on fusions that affect tyrosine kinase signaling, and to highlight theimportance of testing for oncogenic fusions. We present an overview of the identification of oncogenic gene fusions and therapiesapproved for the treatment of cancers harboring gene fusions, and summarize data regarding treating fusion-positive cancers withno current targeted therapies and clinical studies of fusion-positive cancers. Although treatment options may be limited for patientswith rare alterations, healthcare professionals should identify patients most likely to benefit from oncogenic gene fusion testingand initiate the appropriate targeted therapy to achieve optimal treatment outcomes.